Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986235 in Healthy Subjects
Latest Information Update: 04 Apr 2022
At a glance
- Drugs BMS 986235 (Primary)
- Indications Inflammation
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 16 Mar 2022 Status changed from active, no longer recruiting to completed.
- 07 Aug 2020 Planned End Date changed from 1 Aug 2020 to 1 Apr 2021.
- 07 Aug 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Apr 2021.